Abstract
Clinical translation of DNA-based administration of monoclonal antibodies (mAbs) is uncertain due to lack of large animal data. To bridge the clinical gap, we evaluated a panel of novel plasmid DNA (pDNA)-encoded mAbs in 40-70 kg sheep with a clinical intramuscular electroporation protocol. Injection of 4.8 mg of pDNA, encoding ovine anti-human CEA mAb (OVAC), led to peak plasma mAb titers of 300 ng/mL. OVAC remained detectable for 3 months and was boosted by a second pOVAC administration. Hyaluronidase muscle pretreatment increased OVAC concentrations up to 10-fold. These higher plasma titers, however, led to anti-drug antibodies (ADAs) toward the OVAC variable regions, resulting in loss of mAb detection and of adequate redosing. Transient immune suppression avoided ADA formation, with OVAC peaking at 3.5 μg/mL and remaining detectable for 11 months after pOVAC injection. DNA-based delivery of ovine anti-human EGFR mAb (OVAE), identical to OVAC except for the variable regions, preceded by hyaluronidase, allowed for at least three consecutive administrations in an immune-competent sheep, without ADA response. When tripling the pOVAE dose to 15 mg, transient ADAs of limited impact were observed; plasma OVAE peaked at 2.6 μg/mL a...Continue Reading
References
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Aug 18, 2001·Gene Therapy·J M McMahonD J Wells
Feb 1, 2002·Gene Therapy·R D WeeratnaH L Davis
Mar 10, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Torunn Elisabeth TjelleBjarne Bogen
Sep 1, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gaëlle VandermeulenVéronique Préat
Nov 20, 2012·Human Gene Therapy Methods·Iben SpanggaardJulie Gehl
Feb 20, 2013·The American Journal of Gastroenterology·Niels Vande CasteeleSéverine Vermeire
Jun 4, 2013·Nature Biotechnology·Alejandro B BalazsDavid Baltimore
Jan 1, 2014·PloS One·Daniel HeylmannBernd Kaina
Jun 5, 2015·Journal of Virology·Kevin O SaundersGary J Nabel
Oct 8, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·José M Martinez-NavioRonald C Desrosiers
May 26, 2016·Journal of Clinical Immunology·Richard L WassermanDavid Gelmont
Jan 31, 2017·Microbial Pathogenesis·Evangelia ChatzinasiouOrestis Papadopoulos
Feb 24, 2017·Therapeutic Drug Monitoring·Ann GilsPaul J Declerck
Mar 3, 2017·Nature Communications·Norbert PardiDrew Weissman
Apr 26, 2017·Acta Oncologica·Iben SpanggaardJulie Gehl
Apr 30, 2017·Gut·Thomas Van StappenAnn Gils
Jun 9, 2017·Journal of Translational Medicine·Kevin Hollevoet, Paul J Declerck
Sep 18, 2017·Molecular Therapy. Nucleic Acids·Alessandra LopesGaëlle Vandermeulen
Sep 28, 2017·British Journal of Cancer·Jeffrey R InfanteRamesh K Ramanathan
Mar 24, 2018·Oncotarget·Kevin HollevoetPaul Declerck
Dec 14, 2018·Nature·Amanda Keener
Apr 10, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·Rianne N EsquivelDavid B Weiner
Citations
Jun 25, 2020·Emerging Microbes & Infections·Chasity D AndrewsRachel A Liberatore
Aug 1, 2020·Cancer Gene Therapy·Giles VermeireKevin Hollevoet
Mar 12, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ami PatelDavid B Weiner
Jun 17, 2020·Human Vaccines & Immunotherapeutics·Katherine SchultheisTrevor R F Smith
Feb 27, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Liesl JacobsKevin Hollevoet
Sep 7, 2021·Human Gene Therapy·Giles VermeireKevin Hollevoet